Cerebral vascular complication and hyperhomocysteinemia in a cystinotic uremic child

Pediatric Nephrology

Volumn 13, Issue 1, 1999, Pages 73-76

  Merouani, A ^a   Genest Jr , J ^b   Rozen, R ^c   Lambert, M ^a   Mitchell, G A ^a   Dubois, J ^a   Robitaille, P ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Cerebrovascular disease; Cystinosis; Folic acid; Homocysteine; Thermolabile methylenetetrahydrofolate reductase variant; Uremia; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADOLESCENT; ARTICLE; BLOOD LEVEL; CASE REPORT; CEREBROVASCULAR DISEASE; CYSTINOSIS; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; PERITONEAL DIALYSIS; PRIORITY JOURNAL; STROKE; UREMIA;

ADOLESCENT; CEREBROVASCULAR DISORDERS; CYSTINOSIS; FEMALE; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 0033040648     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670050567     Document Type: Article

References (28)

1. Mudd SH, Levy HL, Skovky (1995) Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease. 7th edn. McGraw-Hill. New York, pp 1279-1327
2. Ueland PM, Refsum H (1989) Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med 114: 473-497
3. Kang SS, Wong PWK, Malinow MR (1992) Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 12: 279-298
4. Goyette P, Summer JS, Milos R, Duncan MV, Rosenblatt DS, Matthews RG, Rozen R (1994) Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 7: 195-200
5. Rozen R (1996) Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 19: 589-594
6. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P (1993) hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43 [Suppl 41]: S72-S77
7. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau MR, Seyhoun E, Hardtman W, Prior R, Wilson PWF, Selhub J (1995) Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case control study. Atherosclerosis 114: 93-103
8. Zidek W (1997) Homocysteine: a new atherosclerotic risk factor in end stage renal disease Nephron 75: 249-50
9. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis WW. (1998) Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end stage-renal disease. Circulation 97: 138-141
10. Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J, Genest J Jr (1996) Plasma homocysteine in healthy subjects: sex-specific relation with biological traits. Am J Clin Nutr 64: 587-593
11. Tonstad S, Refsum H, Siverston M, Christopherson B, Ose L, Ueland PM (1996) Relation of total homocysteine and lipid levels in children to premature cardiovascular death in males relatives. Pediatr Res 40: 47-52
12. 12 and homocysteine in an healthy group of adolescents: relation to the methylenetetrahydrofolate reductase (MTHFR) genotype (abstract). 7th International Congress on Pediatric Laboratory Medicine, 30 Sept-4 Oct 1998, Estorial, Portugal
13. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mattews RG, Boers GJH, Heijer M den, Kluikmans LA, Heuvel LP van der, Rozen R (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113
14. United States Renal Data System (1995) USRDS Annual Report. Am J Kidney Dis 26 [Suppl 2]: S85-S94
15. Report from the European Dialysis and Transplant Association (EDTA) registry (1986) Demography of dialysis and transplantation in children in Europe. Nephrol Dial Transplant 1: 9-15
16. Arnodottir M, Hultberg B, Nilsson-Ehle P, Thysell H (1996) The effect of reduced glomerular filtration rate on plasma total homocysteine concentration . Scand J Clin Lab Invest 56: 41-46
17. Haworth JC, Dilling LA, Surtees RA, Seargeant LE, Lue-Shing H, Cooper BA, Rosenblatt DS (1993) Symptomatic and asymptomatic methylenetetrahydrofolate reductase deficiency in two adults brothers. Am J Med Genet 45: 572-576
18. Berg M van der, Berg MS van der, Boers GH, Stehouwer CD, Rauwerda JA, Valk J (1995) Hyperhomocysteinemia: with reference to its neuroradiological aspects (review). Neuroradiology 37: 403-411
19. Jacobsen DW (1996) Serum and erythrocyte folates: a matter of life and premature death. Clin Chem 42: 1579-1581
20. 6, pyridoxal phosphate and folate. Am J Cardiol 75: 1107-1111
21. Bostom AG, Lathrop L (1997) Hyperhomocysteinemia in end stage renal disease: prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 52: 10-20
22. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendrich A, Selhub J, Rosenberg IH (1996) High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49: 147-152
23. Wilcken DE, Dudman NP, Tyrrell PA, Robertson MR (1988) Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 35: 697-701
24. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P. Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J, Rosenberg IH (1996) Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123: 193-202
25. 12 levels in chronic high-flux hemodialysis patients. Nephron 75: 259-263
26. Mozani G, Bergesio F, Ciuti R, Rosati A, Frizzi V, Serruto A, Vitali D, Benucci A, Tosi PL, Blandini S (1996) Lipoprotein abnormalities in chronic renal failure and dialysis patients. Blood Purif 14: 262-272
27. Broyer M, Tete MJ, Guest G, Bertheleme JP, Labrousse F, Poisson M (1996) Clinical polymorphism of cystinosis encephalopathy. Results of treatment with cysteamine. J Inherit Metab Dis 9: 65-75
28. Welch GN, Upchurch GR Jr, Loscalzo J (1997) Homocysteine, oxidative stress and vascular disease. Hosp Pract 32: 81-92